Journals / Viral Hepatitis Journal / 2017 / Cilt: 23 - Sayı: 1

Elbasvir/Grazoprevir Experience - A New Glance at HCV Treatment: Case Report

HCV Tedavisinde Yeni Bir Bakış Elbasvir/Grazoprevir Deneyimi: Olgu Sunumu

Pages
34–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications.
📊
Key Findings & Data:With the new treatment options, it is easy to manage with higher rates of success.
💡
Conclusion & Impact:Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications. With the new treatment options, it is easy to manage with higher rates of success. Among them, one of the most recent one is elbasvir/grazoprevir option. This study presents the results of two treatment-naive patients treated with elbasvir/grazoprevir. The first case was a male non-cirrhotic patient and the second one was a female who suffered from compensated hepatic cirrhosis. Both patients received elbasvir/grazoprevir 50/100 mg in a single tablet for 12 weeks. Persistent viral response was achieved in both patients and no side effect was observed during the treatment. Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable

Özet

Hepatit C dünya genelinde önemini sürdüren ve karaciğer komplikasyonları açısından da hala risk oluşturan bir viral hastalıktır. Yeni tedavi seçenekleri ile yöntemi daha kolay ve başarısı daha yüksektir. Bunlar içersinden en yenilerden biri de elbasvir/grazoprevir seçeneğidir. Bu çalışmada elbasvir/grazoprevir tedavisi alan iki hastamıza ait sonuçlar paylaşıldı. İki olgunun değerlendirildiği bu çalışmada olgularımızdan ikisi de tedavi deneyimsiz olup; birinci olgu non-sirotik erkek hasta diğeri ise kompanse karaciğer sirozu olan kadın hastadır. Her iki hasta 12 haftalık elbasvir/grazoprevir 50/100 mg tek doz tablet ile tedavi edildi. Her iki hastada da kalıcı viral yanıt elde edilirken ilaç kullanımı esnasında da herhangi bir yan etki izlenmedi. Yeni tedavi seçeneklerinden biri olan elbasvir/grazoprevir kombinasyonu hem etkin hem de tolere edilebilir olarak değerlendirildi

🔖

Cite This Article

ÇELEN, M. K., KALKAN, İ. A., TEKİN, R., BAYAN, K., AYAZ, C. (2017). Elbasvir/Grazoprevir Experience - A New Glance at HCV Treatment: Case Report. Viral Hepatitis Journal, Cilt: 23 - Sayı: 1, 34–36. https://ajindex.com/articles/332674

References (5)

  1. Papudesu C, Kottilil S, Bagchi S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int. 2016
  2. El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016:1-9
  3. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, openlabel trial. Lancet HIV. 2015;2:e319-327
  4. Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, AsanteAppiah E, Wahl J, Nguyen BY, Barr E, Platt HL. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ ribavirin: A phase III randomized controlled trial. J Hepatol. 2016;65:1112-1119
  5. Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016;23:80-88.